Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SND-207-N
- Development stage
- Preclinical
- Lead developer
- Floratek Pharma
- Modality
- Small Molecules
- Administration
- Intratumoral
01
Overview
SND-207-N is a plant-derived small molecule inhibitor targeting Protein Kinase N1 (PKN1), currently under development by Floratek Pharma. PKN1 is a serine/threonine-protein kinase involved in various cellular signaling pathways, including those regulating cell cycle progression, migration, and survival, which are often dysregulated in hematological malignancies. SND-207-N is being investigated for the treatment of lymphoma. As of 2024, the program is in the preclinical stage, with discovery and efficacy studies completed or ongoing, and IND-enabling studies currently in progress.
- Other names
- SND-207-NSND207-NSND 207-N
02
Targets
PAK1 (p21-activated kinase 1)
Beyond the preview
Go deeper on SND-207-N.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SND-207-N.